These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 37649926)

  • 1. Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances.
    Ekhator C; Qureshi MQ; Zuberi AW; Hussain M; Sangroula N; Yerra S; Devi M; Naseem MA; Bellegarde SB; Pendyala PR
    Cureus; 2023 Aug; 15(8):e44302. PubMed ID: 37649926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobiotechnology-based drug delivery to the central nervous system.
    Jain KK
    Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies.
    Ding S; Khan AI; Cai X; Song Y; Lyu Z; Du D; Dutta P; Lin Y
    Mater Today (Kidlington); 2020; 37():112-125. PubMed ID: 33093794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.
    Yang J; Luly KM; Green JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1853. PubMed ID: 36193561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as New Generations of Blood-Brain Barrier Transmitters.
    Amiri M; Jafari S; Kurd M; Mohamadpour H; Khayati M; Ghobadinezhad F; Tavallaei O; Derakhshankhah H; Sadegh Malvajerd S; Izadi Z
    ACS Chem Neurosci; 2021 Dec; 12(24):4475-4490. PubMed ID: 34841846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Nanoparticle Approaches in Nose to Brain Drug Delivery and Anticancer Therapy - A Review.
    Ansari MA; Chung IM; Rajakumar G; Alzohairy MA; Alomary MN; Thiruvengadam M; Pottoo FH; Ahmad N
    Curr Pharm Des; 2020; 26(11):1128-1137. PubMed ID: 31951165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier.
    Tan Q; Zhao S; Xu T; Wang Q; Lan M; Yan L; Chen X
    J Mater Chem B; 2022 Nov; 10(45):9314-9333. PubMed ID: 36349976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
    Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
    J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
    Gidwani M; Singh AV
    Curr Pharm Biotechnol; 2014; 14(14):1201-12. PubMed ID: 24809717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current approaches to facilitate improved drug delivery to the central nervous system.
    Markowicz-Piasecka M; Darłak P; Markiewicz A; Sikora J; Kumar Adla S; Bagina S; Huttunen KM
    Eur J Pharm Biopharm; 2022 Dec; 181():249-262. PubMed ID: 36372271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
    Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
    Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.